Johnson & Johnson Says Its One-Dose Coronavirus Vaccine Was 66% Effective in Clinical Trial

Johnson & Johnson (NYSE: JNJ) released results today from the phase 3 clinical trial of its COVID-19 vaccine candidate, saying that the data showed it was 66% effective against moderate and severe disease, 85% effective against severe disease, and completely prevented hospitaRead MoreMarketsMarkets Feed

¡Haz clic para votar esta entrada!
(Votos: 0 Promedio: 0)

Deja un comentario